Who we are

Through our expertise in research and development, regulatory and business development, we develop innovative clinically proven, insight-led and effective products to support our customers in the growing sexual health market.

Futura Medical is based in Guildford, United Kingdom (“UK”) and is listed on the AIM market of the London Stock Exchange. We are an agile, driven and committed team with extensive experience in the research, development and commercialisation of consumer health products in all of the key global consumer healthcare markets.

Futura’s business model is based on a hybrid R&D and commercial strategy, providing flexibility to develop the most appropriate commercial structure by market. Futura has distribution or license partners in place for Eroxon^® in a number of major consumer markets and we continue to seek new market opportunities with leading consumer healthcare companies to drive long-term sustainable market growth.

Eroxon^®, Futura's clinically proven lead project, has been developed for the treatment of erectile dysfunction (“ED”). Eroxon^® is now approved and available to purchase in 27 markets across the world including in much of Europe and the USA. It is the only known regulatory approved topical gel treatment for ED available without the need of a doctor’s prescription. Eroxon^® is proven to help men get an erection fast and can be used as part of foreplay, helping to restore intimacy and sexual spontaneity addressing significant unmet needs in the ED market.

WSD4000 (project name), Futura’s new portfolio for female sexual health, is in the development phase and currently focuses on a range of topical gels specifically designed to treat impaired sexual response or function (sexual dysfunction) in women. WSD4000 will address significant gaps in the market for treating and supporting women’s sexual health.